标题
Enhancing the evaluation of PI3K inhibitors through 3D melanoma models
作者
关键词
-
出版物
Pigment Cell & Melanoma Research
Volume 29, Issue 3, Pages 317-328
出版商
Wiley
发表日期
2016-02-06
DOI
10.1111/pcmr.12465
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Maximizing the Efficacy of MAPK-Targeted Treatment in PTEN LOF /BRAF MUT Melanoma through PI3K and IGF1R Inhibition
- (2015) Barbara Herkert et al. CANCER RESEARCH
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- AKT1 Activation Promotes Development of Melanoma Metastases
- (2015) Joseph H. Cho et al. Cell Reports
- 3D cell culture systems modeling tumor growth determinants in cancer target discovery
- (2014) Claudio R. Thoma et al. ADVANCED DRUG DELIVERY REVIEWS
- Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
- (2014) T. Katsila et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
- (2014) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma
- (2014) Darshil J. Shah et al. MAYO CLINIC PROCEEDINGS
- BRAF V600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
- (2014) Jillian M. Silva et al. MOLECULAR CANCER RESEARCH
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013
- (2014) Adina Vultur et al. Pigment Cell & Melanoma Research
- Decatenation checkpoint-defective melanomas are dependent on PI3K for survival
- (2014) Kelly Brooks et al. Pigment Cell & Melanoma Research
- PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
- (2014) Marian M. Deuker et al. Cancer Discovery
- Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling
- (2014) M. Will et al. Cancer Discovery
- A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
- (2013) J. F. Grippo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
- (2013) Victoria Marsh Durban et al. JOURNAL OF CLINICAL INVESTIGATION
- HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
- (2013) Gregg L. Semenza JOURNAL OF CLINICAL INVESTIGATION
- MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines
- (2013) A Vultur et al. ONCOGENE
- High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells
- (2013) Vesa Hongisto et al. PLoS One
- Nutrient signaling to mTOR and cell growth
- (2013) Jenna L. Jewell et al. TRENDS IN BIOCHEMICAL SCIENCES
- Spheroid culture as a tool for creating 3D complex tissues
- (2013) Eelco Fennema et al. TRENDS IN BIOTECHNOLOGY
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- The Role of the PI3K-AKT Pathway in Melanoma
- (2012) Michael A. Davies CANCER JOURNAL
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
- (2012) Austin Y. Shull et al. PLoS One
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
- (2011) W. Deng et al. Pigment Cell & Melanoma Research
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
- (2009) R. Marone et al. MOLECULAR CANCER RESEARCH
- Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
- (2008) K. S.M. Smalley et al. CANCER RESEARCH
- SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
- (2008) A. Vultur et al. MOLECULAR CANCER THERAPEUTICS
- Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking
- (2008) Linda V Sinclair et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started